GlassScriptPhysician profile
Mitchell T Cabisudo
NPI 1801055561
$346,209.30
in general payments reported to CMS, 2019-2025
26 companies · $23K in 2025
The $23K reported for 2025 was more than what 98% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58K · 2020: $16K · 2021: $55K · 2022: $59K · 2023: $77K · 2024: $58K · 2025: $23K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $119K · Travel and Lodging: $22K · Food and Beverage: $8,729 · Consulting Fee: $7,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $119,375.00 |
| Travel and Lodging | $21,871.52 |
| Food and Beverage | $8,728.91 |
| Consulting Fee | $7,300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $168,897.79 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $95,458.47 | 2020-2025 | Caplyta |
| Allergan, INC. | $71,985.73 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $2,745.20 | 2021-2025 | Qelbree, Qelbree |
| Janssen Pharmaceuticals, INC | $2,190.21 | 2019-2023 | Spravato |
| Alkermes, INC. | $1,431.83 | 2021-2025 | Lybalvi, Aristada |
| Corium, LLC | $582.42 | 2022-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $493.28 | 2019-2024 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $480.87 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Mycite |
| Takeda Pharmaceuticals U.S.A., INC. | $315.59 | 2019-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $260.26 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $218.93 | 2020-2024 | Austedo Xr |
| Axsome Therapeutics, INC. | $199.96 | 2023-2024 | Auvelity |
| Indivior INC. | $172.99 | 2019-2024 | Sublocade |
| Neurocrine Biosciences, INC. | $155.82 | 2019-2024 | Ingrezza |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $120.64 | 2019 | |
| Bausch Health US, LLC | $101.16 | 2021-2023 | Aplenzin |
| Neos Therapeutics, LP | $78.21 | 2020-2024 | Adzenys Xr-Odt |
| E.R. Squibb & Sons, L.L.C. | $65.18 | 2025 | Cobenfy |
| Orexo US, INC. | $50.29 | 2019-2022 | |
| Tris Pharma INC | $50.18 | 2022-2025 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $41.68 | 2019-2020 | |
| Validus Pharmaceuticals LLC | $38.17 | 2023 | Equetro |
| Jazz Pharmaceuticals INC. | $37.43 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $22.60 | 2019 | |
| Neuronetics, INC. | $14.41 | 2024 | Neurostar Tms Therapy System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Cabisudo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.